Skip to main content
Clinical Trials/NCT04758078
NCT04758078UnknownNot Applicable

Inhaled Budesonide in Transient Tachypnea of the Newborn: A Randomized, Placebo-controlled Study

Makassed General Hospital2 sites in 1 country50 target enrollmentStarted: February 15, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
50
Locations
2
Primary Endpoint
Assessment of respiratory distress

Study Overview

Brief Summary

Background: Transient tachypnea of the newborn (TTN) caused by lung edema resulting from delayed absorption of fetal alveolar lung fluid and is a common cause of admission of late preterm and full-term infants to neonatal intensive care units. Infant born by C-section and those with perinatal asphyxia, umbilical cord prolapse or certain maternal condition (asthma, diabetes, or analgesia) are more prone to develop TTN. Conventional treatment involves appropriate oxygen administration and continuous positive airway pressure in some cases. Hastening the clearance of lung liquid should shorten the duration of the symptoms and reduce complications.

Objectives: This study aims to determine the effectiveness of inhaled budesonide in the treatment of this disorder through determining whether it reduces the duration of oxygen therapy and respiratory symptoms and shortens hospital stay in term infants with transient tachypnea of the newborn

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
34 Weeks to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Late preterm and term infants (post-menstrual age ≥ 34 weeks) delivered by Cesarean section or vaginal delivery
  • Diagnosis of transient tachypnea of the newborn
  • The need for Continuous positive airway pressure (CPAP) >6 hours to obtain the oxygen saturation >92%

Exclusion Criteria

  • Meconium aspiration syndrome;
  • Respiratory distress syndrome
  • Congenital heart Disease
  • Non respiratory disorders causing tachypnea (polycythemia or hypoglycemia) resolving with treatment of the disorder
  • Pneumonia by chest x-ray
  • Suspected sepsis/bacteremia
  • Prenatal steroids

Outcomes

Primary Outcomes

Assessment of respiratory distress

Time Frame: within 48 hours

Transient tachypnea of the newborn clinical score

Secondary Outcomes

  • Assessment of time to spontaneous breathing(with 48 hours)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dr. Sirin Mneimneh

Pediatrician

Makassed General Hospital

Study Sites (2)

Loading locations...

Similar Trials